

MAR 05 2004
 PAT & TRADEMARK OFFICE

Information Disclosure Statement List By Applicant Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number MLY-2-DIV-CIP	Serial Number 10/726,160
	Applicant Nancy Y. Ip et al.	
	Filing Date: December 2, 2003	Group Unknown 1643
Confirmation No.: Unknown		

NOTE: If no indication is made in the column marked "COPY NOTE," the required legible copy of the corresponding item is submitted herewith; otherwise, a copy is not required and/or not submitted, for the following reason(s) [corresponding reason number is listed in "COPY NOTE" column]

(1) This item is cumulative, per Rule 98(c)
 (2) A copy of this item was previously cited by or submitted to the U.S. Patent and Trademark Office in:
 USSN _____, filed _____, or
 USSN _____, filed _____;
 Relied on under 35 U.S.C. Section 120, per Rule 98(d)
 (3) Both reasons (1) and (2) apply
 (4) No legible complete copy is possessed, in custody of controlled, or readily available

U.S. PATENT DOCUMENTS											
EXAMINER INITIALS	PATENTEE NAME	PATENT NUMBER								ISSUE DATE	COPY NOTE
anh	Hillman et al.	5	8	5	6	1	2	9		1/5/1999	

FOREIGN PATENT DOCUMENTS											
EXAMINER INITIALS	COUNTRY	DOCUMENT NUMBER								PUBLICATION DATE	TRANSLATION
											YES NO N/A

*"NO" means that no copy of an English language translation is within the possession, custody, or control of, or is readily available to any individual designated in Rule 56(c).

EXAMINER INITIALS	OTHER DOCUMENTS	COPY NOTE
anh	Specify author (if any), Title, Pertinent Pages, Date & Place of Publication Lewin, Benjamin. Genes IV, Oxford University Press, p.810 Cambridge, 1990.	
↓	Nucleic acid database, Accession #A1023761 1998	
↓	Nucleic acid database, Accession #AA913841 1998	
↓	Nucleic acid database, Accession #AA846697 1998	
EXAMINER	DATE CONSIDERED	
Examiner: initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.		

(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: MLY-2-DIV-CIP	Serial Number: 10/726,160
	Applicant: Ip, et al.	
	Filing Date: December 2, 2003 Confirmation No: Unknown	Group Art Unit: Unknown 1643

NOTE:

If no indication is made in the column marked "COPY NOTE," the required legible copy of the corresponding item is submitted herewith; otherwise, a copy is not required and/or not submitted, for the following reason(s) [corresponding reason number is listed in "COPY NOTE" column]

- (1) This item is cumulative, per Rule 98(c)
- (2) A copy of this item was previously cited by or submitted to the U.S. Patent and Trademark Office in:
 USSN _____, filed _____, or
 USSN _____, filed _____;
 Relied on under 35 U.S.C. Section 120, per Rule 98(d)
- (3) Both reasons (1) and (2) apply
- (4) No legible complete copy is possessed, in custody of controlled, or readily available
- (5) Per the U.S. Patent and Trademark Office's waiver of Rule 98(a)(2)(i), the item is a U.S. patent or patent application publication, and the present application was filed after June 30, 2003.

U.S. PATENT DOCUMENTS									
EXAMINER INITIALS	PATENTEE NAME	PATENT NUMBER				ISSUE DATE	COPY NOTE		

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIALS	COUNTRY	DOCUMENT NUMBER	PUBLICATION DATE	TRANSLATION			COPY NOTE
				YES	NO	N/A	

*"NO" means that no copy of an English language translation is within the possession, custody, or control of, or is readily available to any individual designated in Rule 56(c).

EXAMINER INITIALS	OTHER DOCUMENTS		COPY NOTE
	Specify author (if any), Title, Pertinent Pages, Date & Place of Publication		
amb	Article - <i>Rising Incidence of Hepatocellular Carcinoma in the United States</i> , Hashem B. El-Serag and Andrew C. Mason, The New England Journal of Medicine, Vol. 340, No. 10, March 11, 1999, pp. 745-750		
	Article - <i>Utilization of Nuclear Matrix Proteins for Cancer Diagnosis</i> , Susan K. Keese, Joseph V. Briggman, Gregory Thill, and Ying-Jye Wu, Critical Reviews in Eukaryotic Gene Expression, Vol. 6, 1996, pp. 189-214		
	Article - <i>Evaluation of the Clinical Value of Urinary NMP22 as a Marker in the Screening and Surveillance of Transitional Cell Carcinoma of the Urinary Bladder</i> , R. Chahal, A. Darshane, A.J. Browning, and S.K. Sundaram, European Urology, Vol. 40, March 14, 2001, pp. 415-421		

BEST AVAILABLE COPY

(Rev. 5/92) Information Disclosure Statement List By Applicant(s) Under 37 CFR Section 1.98(a) (1) (Use several sheets if necessary)	Attorney Docket Number: MLY-2-DIV-CIP	Serial Number: 10/726,160
	Applicant: Ip, et al.	
	Filing Date: December 2, 2003 Confirmation No: Unknown	Group Art Unit: Unknown 1643

amh	Article – <i>Nuclear matrix proteins as biomarkers for breast cancer</i> , Diana Lüftner and Kurt Possinger, <i>Expert. Rev. Mol. Diagn.</i> , Vol. 2, 2002, pp. 23-31		
	Article – <i>Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma</i> , P. Grabowski, T. Kühnel, F. Mühr-Wilkensoff, B. Heine, H. Stein, M. Höpfner, C.T. Germer, and H. Scherübl, <i>British Journal of Cancer</i> , Vol. 88, 2003, pp. 115-119		
	Article – <i>T c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma</i> , J. S. Chana, R. Grover, P. Tulley, H. Lohrer, R. Sanders, A. O. Grobbelaar, and G. D. Wilson, <i>British Journal of Plastic Surgery</i> , Vol. 55, 2002, pp. 623-627		
	Estimated New Cancer Cases and Deaths by Sex, US, 2003, from <i>Cancer Facts & Figures 2003</i> , American Cancer Society, Inc., Surveillance Research, 2 pages		
	Percentage Distribution of Microscopically Verified Cases by Histological Type Liver (ICD-9 155) – Both Sexes from <i>Cancer Incidence in Five Continents</i> , Vol. VII, D.M. Parkin, S.L. Whelan, J. Ferlay, L. Raymond, and J. Young, IARC Scientific Publications No. 143, 1997, pp. 1072-1074		
EXAMINER amh		DATE CONSIDERED 15 Nov 2006	
Examiner: initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.			